---
layout: default
title: Sitagliptin
parent: AI Predictions (L5)
nav_order: 545
evidence_level: L5
indication_count: 10
---

# Sitagliptin
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sitagliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia

## One-Sentence Summary

> Sitagliptin is a DPP-4 inhibitor established for glycemic control in type 2 diabetes mellitus.
> The TxGNN model assigns a very high score to **Opsismodysplasia**, a rare genetic skeletal dysplasia, as a predicted new indication.
> However, this prediction is currently supported by **zero clinical trials and zero literature citations**, and the evidence pack itself flags it as a likely statistical false positive with no known mechanistic basis.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not captured in this regulatory dataset (Sitagliptin is a well-established DPP-4 inhibitor used for Type 2 Diabetes Mellitus) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 98.87% |
| Evidence Level | L5 (model prediction only, no clinical or literature evidence) |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for Sitagliptin is not available in this evidence pack (data gap, severity: High). Based on general pharmacological knowledge referenced throughout the accompanying literature, Sitagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, which prolongs the activity of endogenous incretin hormones (GLP-1/GIP) to enhance glucose-dependent insulin secretion in type 2 diabetes.

Opsismodysplasia is a rare autosomal recessive skeletal dysplasia caused by mutations in the *INPPL1* gene, affecting bone growth and ossification. There is no established biological pathway connecting DPP-4/incretin signaling to *INPPL1*-mediated skeletal development.

The evidence pack's own mechanistic assessment explicitly states that this high TxGNN score likely reflects a **statistical false positive arising from sparse knowledge-graph nodes**, rather than genuine mechanistic plausibility. No preclinical, clinical, or case-level evidence supports this drug-disease link, and the recommendation at this stage is correctly **Hold**.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## EU Market Information

No EU marketing authorizations are on record for Sitagliptin in this dataset (`total_licenses: 0`, market status: Not Marketed).

---

## Safety Considerations

Please refer to the SmPC for safety information.

*Note: Two data gaps affect safety assessment — TFDA/EMA label warnings and contraindications are unavailable (severity: **Blocking**, prevents entry into Stage 1 safety review), and detailed MOA data is unavailable (severity: High). A DDI query returned no results (`query_status: not_found`).*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN numerical score, the top-ranked predicted indication (Opsismodysplasia) has no clinical trials, no literature support, and no plausible mechanistic link per the evidence pack's own assessment — it is explicitly flagged as a probable statistical artifact. Additionally, a blocking data gap (missing TFDA/EMA label safety information) prevents this candidate from advancing past Stage 0.

**To proceed, the following is needed:**
- TFDA/EMA product label (warnings, contraindications) — currently blocking further safety evaluation
- Confirmed mechanism of action documentation for Sitagliptin
- Independent mechanistic or preclinical evidence specifically linking DPP-4 inhibition to *INPPL1*-related skeletal dysplasia, if this candidate is to be pursued further
- Given the near-total absence of supporting evidence, review of lower-ranked candidates in this pack (e.g., rank 6, pancreatic agenesis, which has L4 literature evidence) may be more productive than continuing to pursue rank 1
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

